provider: openai_compatible | deep: kimi-k2.6 | quick: kimi-k2.6
Analyzing CORT for 2026-10-02
================================ Human Message =================================

CORT
================================== Ai Message ==================================

I'll analyze CORT (Corcept Therapeutics). Let me start by retrieving the price data and a verified market snapshot.
Tool Calls:
get_stock_data (tool_Yr5QOZ03136HPusHGFaieFVX)
Call ID: tool_Yr5QOZ03136HPusHGFaieFVX
Args:
symbol: CORT
start_date: 2026-04-02
end_date: 2026-10-02
get_verified_market_snapshot (tool_nEabJ6x6GptZiESjNshdrBsx)
Call ID: tool_nEabJ6x6GptZiESjNshdrBsx
Args:
symbol: CORT
curr_date: 2026-10-02
look_back_days: 30
================================= Tool Message =================================
Name: get_verified_market_snapshot

Verified market data snapshot for CORT

Requested analysis date: 2026-10-02
Latest trading row used: 2026-10-01
Rows after the requested analysis date are excluded before verification.

Latest verified OHLCV row

Field	Value
Open	114.29
High	115.98
Low	111.94
Close	114.03
Volume	879000

Verified technical indicators (latest row)

Indicator	Value
close_10_ema	114.80
close_50_sma	112.61
close_200_sma	69.78
rsi	50.54
boll	113.99
boll_ub	118.33
boll_lb	109.65
macd	0.89
macds	1.09
macdh	-0.20
atr	5.23

Recent verified closes (last 30 rows)

Date	Close
2026-08-20	121.05
2026-08-21	122.25
2026-08-24	123.24
2026-08-25	123.57
2026-08-26	119.80
2026-08-27	116.93
2026-08-28	113.88
2026-08-31	113.35
2026-09-01	113.38
2026-09-02	110.43
2026-09-03	112.80
2026-09-04	111.62
2026-09-08	113.98
2026-09-09	115.70
2026-09-10	114.92
2026-09-11	112.79
2026-09-14	111.80
2026-09-15	110.82
2026-09-16	111.81
2026-09-17	114.86
2026-09-18	110.29
2026-09-21	113.76
2026-09-22	117.51
2026-09-23	112.94
2026-09-24	118.51
2026-09-25	116.10
2026-09-28	115.63
2026-09-29	114.74
2026-09-30	115.23
2026-10-01	114.03

Use this snapshot as the source of truth for exact OHLCV, price-level, and indicator-value claims. If another tool output conflicts with it, flag the discrepancy rather than inventing a reconciled number. Do not claim historical validation, support/resistance bounces, or exact percentage moves unless directly supported by tool output with concrete dates and prices.
================================== Ai Message ==================================

Now let me pull the most complementary indicators to characterize the current regime — trend (50/200 SMA), short-term momentum (10 EMA, MACD, RSI), volatility (Bollinger, ATR), and volume (VWMA).
Tool Calls:
get_indicators (tool_XRoT5dM78Qhl8cTJaB8Hueh8)
Call ID: tool_XRoT5dM78Qhl8cTJaB8Hueh8
Args:
symbol: CORT
indicator: close_50_sma
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_MLFRI3bi1vCWy2BjiTyDxmii)
Call ID: tool_MLFRI3bi1vCWy2BjiTyDxmii
Args:
symbol: CORT
indicator: close_200_sma
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_l1FTIg3Prt0VX7lRUBCbxkz1)
Call ID: tool_l1FTIg3Prt0VX7lRUBCbxkz1
Args:
symbol: CORT
indicator: close_10_ema
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_nPbmza7Gz03viiEFt2Bq3UQ4)
Call ID: tool_nPbmza7Gz03viiEFt2Bq3UQ4
Args:
symbol: CORT
indicator: macd
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_mXgIWQ76M0RORjz3u4VBkbYB)
Call ID: tool_mXgIWQ76M0RORjz3u4VBkbYB
Args:
symbol: CORT
indicator: rsi
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_7EbfN6s7YIX9qsltRl9B25Cu)
Call ID: tool_7EbfN6s7YIX9qsltRl9B25Cu
Args:
symbol: CORT
indicator: boll
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_cYGVH7AG9Lq2oCXwSedanFkB)
Call ID: tool_cYGVH7AG9Lq2oCXwSedanFkB
Args:
symbol: CORT
indicator: atr
curr_date: 2026-10-02
look_back_days: 60
get_indicators (tool_nVhzAfyc8JVD6r0Ai58osLB2)
Call ID: tool_nVhzAfyc8JVD6r0Ai58osLB2
Args:
symbol: CORT
indicator: vwma
curr_date: 2026-10-02
look_back_days: 60
================================= Tool Message =================================
Name: get_indicators

vwma values from 2026-08-03 to 2026-10-02:

2026-10-02: N/A: Not a trading day (weekend or holiday)
2026-10-01: 113.09938081522421
2026-09-30: 113.0827788090977
2026-09-29: 113.04639627862512
2026-09-28: 112.99667861785885
2026-09-27: N/A: Not a trading day (weekend or holiday)
2026-09-26: N/A: Not a trading day (weekend or holiday)
2026-09-25: 112.87568540474861
2026-09-24: 112.72548380458245
2026-09-23: 112.59099986414584
2026-09-22: 112.50496147469087
2026-09-21: 112.43056800644203
2026-09-20: N/A: Not a trading day (weekend or holiday)
2026-09-19: N/A: Not a trading day (weekend or holiday)
2026-09-18: 112.41106234235225
2026-09-17: 112.8983396922237
2026-09-16: 113.12219902884593
2026-09-15: 113.7941039342706
2026-09-14: 114.94164984959322
2026-09-13: N/A: Not a trading day (weekend or holiday)
2026-09-12: N/A: Not a trading day (weekend or holiday)
2026-09-11: 115.80292665860563
2026-09-10: 116.44408398810526
2026-09-09: 116.7496078931744
2026-09-08: 117.0027774371673
2026-09-07: N/A: Not a trading day (weekend or holiday)
2026-09-06: N/A: Not a trading day (weekend or holiday)
2026-09-05: N/A: Not a trading day (weekend or holiday)
2026-09-04: 117.49399601593412
2026-09-03: 117.78128405190016
2026-09-02: 117.78029617485305
2026-09-01: 117.87295809416744
2026-08-31: 117.98200197908767
2026-08-30: N/A: Not a trading day (weekend or holiday)
2026-08-29: N/A: Not a trading day (weekend or holiday)
2026-08-28: 117.93494286954821
2026-08-27: 117.60891934190177
2026-08-26: 117.05210822785448
2026-08-25: 116.14190740705097
2026-08-24: 115.02982865545992
2026-08-23: N/A: Not a trading day (weekend or holiday)
2026-08-22: N/A: Not a trading day (weekend or holiday)
2026-08-21: 113.91872478317173
2026-08-20: 113.26219249418756
2026-08-19: 113.11508873131488
2026-08-18: 113.31437575708517
2026-08-17: 111.38940870588144
2026-08-16: N/A: Not a trading day (weekend or holiday)
2026-08-15: N/A: Not a trading day (weekend or holiday)
2026-08-14: 110.39888338188172
2026-08-13: 108.86980483668117
2026-08-12: 108.09289346841716
2026-08-11: 107.27402139943514
2026-08-10: 106.064965571223
2026-08-09: N/A: Not a trading day (weekend or holiday)
2026-08-08: N/A: Not a trading day (weekend or holiday)
2026-08-07: 105.11840752266248
2026-08-06: 103.86426246550621
2026-08-05: 102.45559253067208
2026-08-04: 101.64834866277523
2026-08-03: 100.49450021560307

VWMA: A moving average weighted by volume. Usage: Confirm trends by integrating price action with volume data. Tips: Watch for skewed results from volume spikes; use in combination with other volume analyses.
================================== Ai Message ==================================

FINAL TRANSACTION PROPOSAL: HOLD (positional bulls), AVOID initiating fresh longs until momentum re-accelerates; tactically bearish/neutral within the range for short-term swing traders.

CORT (Corcept Therapeutics) — Detailed Trend & Momentum Analysis

As of latest verified close: Thursday, 2026-10-01 | Close $114.03 (Note: 2026-10-02 is a weekend/non-trading day in the dataset)

1. Executive Summary & Indicator Selection Rationale

CORT has undergone a massive, sustained uptrend — roughly tripling from ~$40 in early April 2026 to a peak of ~$123.57 (2026-08-25) — and has spent the last ~5 weeks in a high-level consolidation/bullish flag between roughly $108 and $120. The stock sits at a decision point: the long-term trend remains powerfully bullish, but short-term momentum has stalled and is actively deteriorating at the margins.

Indicators selected (8, non-redundant): close_200_sma, close_50_sma, close_10_ema, macd (+ signal/histogram read from the verified snapshot), rsi, boll (middle, with upper/lower bands from snapshot), atr, vwma. This set spans trend (3 horizons), momentum (2), volatility/range (2), and volume-price confirmation (1) — each answering a distinct question about the current regime.

2. Trend Structure: Bullish Across All Timeframes, but Decelerating

Horizon	Indicator (10-01 value)	Price Relationship	Interpretation
Long-term	200 SMA: $69.78	Price +63% above	Secular uptrend fully intact
Medium-term	50 SMA: $112.61	Price +1.2% above	Trend intact but flattening base
Short-term	10 EMA: $114.80	Price −0.7% below	Momentum has rolled over

The 50 SMA has risen every single session from $84.82 (08-03) to $112.61 (10-01) — an unbroken ~$28 climb over two months. This is a strong dynamic support shelf. The 200 SMA has similarly ground higher from $62.01 to $69.78. There is no death-cross risk whatsoever; the moving-average stack remains perfectly ordered (10 EMA > 50 SMA > 200 SMA).
Key nuance: price closed at $114.03, marginally below the 10 EMA ($114.80) for the most recent session after oscillating around it since mid-September. The 10 EMA itself has gone flat (~$114.8–115.0 for the last week), confirming short-term momentum exhaustion rather than active distribution.
The 50 SMA at ~$112.6 and the VWMA at ~$113.1 form a confluent support zone ($112.5–113.5) that has absorbed every pullback since early September.

Verdict: Strategic trend = bullish. Tactical trend = neutral/slightly soft.

3. Momentum: Rolling Over from Overbought, Not Yet Oversold

RSI: 50.54 — dead-neutral. This is a dramatic normalization from the 72+ readings in late August (peak overbought zone 08-21 to 08-25). Importantly, during the entire September consolidation RSI has held the 45–58 band, never dipping below ~46.6 (09-18). This is classic bullish consolidation behavior — sellers have been unable to push momentum into oversold territory.
MACD: 0.89 vs. Signal 1.09 → Histogram −0.20 — the MACD line crossed below its signal line and the histogram has gone negative. The MACD line has collapsed from a peak of 7.23 (08-25) to 0.89 — a ~88% decay. While MACD remains above zero (no trend-reversal signal), the bearish crossover warns that upside impetus has faded. Momentum traders should treat this as a yellow flag, not a sell trigger, given the zero-line support.

4. Volatility & Range: Post-Spike Compression

ATR: 5.23 — down from 6.06 (08-03) and well off the spike highs seen around the 07-30 gap (the $92.95→$118.32 candle on 4.5M volume). Volatility is contracting as the flag forms — typical and constructive.
Bollinger snapshot: Middle $113.99 | Upper $118.33 | Lower $109.65 — price ($114.03) sits essentially on the mid-band, with the bands relatively tight (bandwidth ≈ 7.6% of price). The market is coiling. The late-August breakdown from the upper band (~$126) to the lower region was orderly, and price has since mean-reverted to the middle — equilibrium.
Notable: the 09-18 session printed 17.23M volume (vs. typical ~0.6–1.5M) with a wide range ($108.41–$117.90) closing at $110.29 — an institutional-scale churn day that resolved sideways rather than downward, suggesting absorption.

5. Volume-Price (VWMA) Confirmation

VWMA: $113.10, with price above it — volume-weighted support is holding. The steady VWMA grind lower from ~$118 (late Aug) to $113 reflects the absence of heavy distribution volume; the 09-18 spike has progressively rolled out of the window without price capitulating. Sustained closes below ~$112.5 would indicate volume-weighted sellers taking control.

6. Actionable Insights

Support levels (evidence-based):
- $112.5–113.5 — 50 SMA ($112.61) + VWMA ($113.10) confluence; also the 09-08 and 09-23 reaction lows zone.
- $109.6–110.8 — Bollinger lower band ($109.65) + the 09-18 ($110.29) and 09-15 ($110.82) closes.
- A decisive break of ~$108 (lower band region, 09-02 low $108.73) would target the rising 50 SMA gap-fill toward $105, and potentially the $100 round number.

Resistance levels:
- $118.3 — Bollinger upper band + 09-24 high ($119.15) + 09-29 high ($120.51) zone.
- $120.4–123.6 — 09-25 high ($120.44), 08-24/08-25 double-top ($123.24/$123.57). A breakout above $123.57 on expanding volume re-opens the trend.

Trade plan:
- Existing holders (HOLD): the secular uptrend and orderly consolidation argue for patience. A trailing stop below the $108–110 zone (roughly 2× ATR under the mid-band) protects against a trend break while allowing the flag to resolve.
- New entries: momentum traders should wait for either (a) a close above ~$118.3–120.5 with MACD histogram turning positive, or (b) a pullback to the $110–112.5 shelf where RSI resets toward 40–45 with a bullish reversal candle.
- Risk: biotech headline risk is inherent; position size per ATR (5.23 ≈ 4.6% of price) — e.g., a $109 stop is ~4.4% below current price.

7. Key Point Summary Table

Category	Indicator	Latest Value	Signal	Weight in Decision
Long-term trend	200 SMA	$69.78	Strongly bullish (+63% above)	Bullish anchor
Medium-term trend	50 SMA	$112.61	Bullish, rising every session; dynamic support	Bullish
Short-term trend	10 EMA	$114.80	Price below it — momentum stalled	Neutral/bearish
Momentum	RSI	50.54	Neutral; constructive consolidation range (46–58)	Neutral
Momentum	MACD / Signal / Hist	0.89 / 1.09 / −0.20	Bearish crossover, above zero — caution	Cautionary
Volatility	ATR	5.23	Contracting; flag forming	Coiling
Range	Bollinger (mid/UB/LB)	113.99 / 118.33 / 109.65	Price at mid-band; breakout watch above 118.3 / below 109.7	Range-bound
Volume-price	VWMA	$113.10	Holding above; no distribution confirmation	Mildly bullish

Bottom line: CORT is a strong stock resting, not a broken one. The weight of evidence favors the consolidation resolving in the direction of the dominant (bullish) trend, but the MACD rollover and loss of the 10 EMA mean the timing isn't confirmed yet. HOLD existing positions with a $108–110 risk line; wait for the range break before adding.
================================ Human Message =================================

Overall Sentiment: Mildly Bullish (Score: 5.5/10)
Confidence: Low

CORT (Corcept Therapeutics) — Sentiment Report, 2026-09-25 → 2026-10-02

1. Source-by-source breakdown

News (Yahoo Finance, past 7 days)

No news found for CORT. There was zero institutional/press coverage in the window. This is meaningful in itself: a clinical-stage-adjacent biotech with no news flow typically means no fresh catalysts, no analyst notes, and no adverse events hitting the wires — sentiment is being driven entirely by the retail channel and anticipation of known upcoming events rather than new information. No institutional framing to anchor against.

StockTwits (8 messages, 2026-09-25 → 2026-10-01)

Labelled sentiment: 1 Bullish (12%), 0 Bearish (0%), 7 Unlabeled (88%) — Total 8 messages. The raw ratio is unusable as a percentage signal (tiny sample, only one label), so the read must come from message content:

@gucag006 (6 of 8 messages) is the dominant voice and carries a constructive, catalyst-oriented thesis:
(09-28, Bullish) Relacorilant FDA/EMA decisions expected by year-end for Cushing's syndrome (US) and PROC (EU); claims US CS approval could double the Korlym/Relacorilant franchise to ~$2B annually.
(10-01) Lifyorli revenue estimate of $80–100M+ for Q3/26, extrapolating from $45M in Q2 with <2 months on market — a revenue-beat expectation.
(10-01) A cautionary counterweight: 9.4M shares short (~9% of outstanding / ~11% of float) means CORT will likely trade sideways until 2026/2027 catalysts (Relacorilant/CS approval, Lifyorli EU approval, Q3 earnings).
(09-26) "IIIINN +400% (Have all the patience in the world)" — long-horizon conviction.
@KINGZIPHER (2 messages): neutral question-asking ("Opinions on Q3?", expectations for Lyforli revenue) — indicates retail attention/engagement without directional commitment.
@EliteTradingGoat (09-25): "OOOOUUTT +21%" — ambiguous slang, plausibly enthusiasm after a ~21% move, but no clear directional thesis.

Net StockTwits read: quietly constructive. Zero bearish labels, the only explicit label is Bullish, and the substance of the thread is revenue-growth math and approval-optionality talk. The one clear negative is structural (short interest → sideways drift), not thesis-breaking.

Reddit (r/wallstreetbets, r/stocks, r/investing)

Unavailable — all three subreddit fetches failed. This is explicitly a tooling failure, not evidence of silence. Reddit signal for CORT this week is unknown and must be treated as missing data, not as neutrality.

2. Cross-source divergences and alignments

Divergence (of a soft kind): News is completely absent while StockTwits shows an active, thesis-driven retail conversation. This pattern — retail positioning ahead of anticipated catalysts with no press confirmation — is classic pre-event chatter. It means the sentiment is expectation-driven, not event-driven, and could whipsaw if a catalyst disappoints or slips.
No conflict: with no news and no Reddit, there is no contradicting source; the mildly bullish read rests entirely on StockTwits content quality.

3. Dominant narrative themes

Lifyorli launch ramp — Q3 revenue expectations ($80–100M+) extrapolated from a $45M partial-quarter Q2; this is the nearest-term (Q3 earnings) driver.
Relacorilant regulatory catalysts — FDA decision for Cushing's syndrome and EMA decision for PROC, expected by year-end 2026; framed as franchise-doubling upside (~$2B annual revenue potential).
Short-interest overhang — ~9% of outstanding / ~11% of float shorted, argued to cap upside and produce sideways trading until catalysts land (this cuts both ways: a squeeze fuel source, or a supply/dampener).
Long-horizon patience — holders expressing multi-year conviction (+400% patience framing).

4. Catalysts and risks surfaced by the data

Catalysts: Q3 earnings report (Lifyorli revenue print vs. the $80–100M whisper number); FDA decision on Relacorilant for Cushing's syndrome (US); EMA decision on Relacorilant for PROC (EU); Lifyorli EU approval.
Risks: Event-timing risk — if regulatory decisions slip into 2027, the sideways-then-up thesis deflates and the short-interest overhang dominates. Whisper-number risk on Q3 Lifyorli revenue ($45M partial quarter → $80–100M is a steep ramp; a miss could trigger a sharp reversal given the retail expectation build-up). Low-conviction-sample risk: the entire signal rests on ~8 messages, ~6 from a single user.

5. Summary table of key sentiment signals

Signal	Direction	Source	Supporting evidence
Labelled sentiment	Mildly Bullish	StockTwits	1 Bullish / 0 Bearish / 7 unlabeled (8 total; weak base rate)
Lifyorli Q3 revenue expectation	Bullish	StockTwits (@gucag006)	$80–100M+ Q3 estimate vs. $45M partial-quarter Q2
Relacorilant approval optionality	Bullish	StockTwits (@gucag006, labelled Bullish)	FDA/EMA decisions by YE2026; US CS approval framed as doubling franchise to ~$2B
Short-interest overhang	Mildly Bearish	StockTwits (@gucag006)	9.4M shares short (~9% outstanding / ~11% float) → sideways drift expected
Retail engagement	Neutral/curious	StockTwits (@KINGZIPHER, @EliteTradingGoat)	Question posts about Q3; "OUT +21%" enthusiasm post
Institutional news flow	Silent	Yahoo Finance	No news found for CORT in window
Reddit community signal	Unknown	r/wsb, r/stocks, r/investing	Fetch failures across all three subreddits — missing, not neutral

Bottom line: CORT sentiment is mildly bullish but resting on a very thin evidentiary base — one dominated user on StockTwits articulating a credible catalyst-and-revenue thesis, no news confirmation, and no Reddit corroboration. The constructive bias is real in content (zero bearish messages, revenue-ramp and approval-optionality narratives) but fragile: expectations for Lifyorli's Q3 print and year-end regulatory decisions are now embedded in retail positioning, so any slip or miss could reverse the tone quickly. Confidence is low due to the single-digit sample, single-user concentration, and two unavailable sources.
================================ Human Message =================================

Proceed with your assigned analysis for this workflow. The instrument to analyze is CORT. Use this exact ticker in every tool call, report, and recommendation, preserving any exchange suffix (e.g. .TO, .L, .HK, .T, -USD). Resolved identity: Company: Corcept Therapeutics Incorporated; Business classification: Healthcare / Biotechnology; Exchange: NCM. Do not substitute a different company or ticker unless a tool result explicitly disproves this resolved identity. The analysis date is 2026-10-02.
================================== Ai Message ==================================
Tool Calls:
get_news (tool_xq28zDDU3m7OIhZMl9HXOVAc)
Call ID: tool_xq28zDDU3m7OIhZMl9HXOVAc
Args:
ticker: CORT
start_date: 2026-09-25
end_date: 2026-10-02
get_global_news (tool_7nT8UsDgMAPGYdu2ChvAQAzQ)
Call ID: tool_7nT8UsDgMAPGYdu2ChvAQAzQ
Args:
curr_date: 2026-10-02
look_back_days: 7
================================= Tool Message =================================
Name: get_global_news

Global Market News, from 2026-09-25 to 2026-10-02:

The Iran war is driving inflation higher — and it's not just because of oil (source: Yahoo Finance)

Link: https://finance.yahoo.com/markets/article/the-iran-war-is-driving-inflation-higher--and-its-not-just-because-of-oil-100000797.html

October may not be as bad for the stock market as investors think: Chart of the Day (source: Yahoo Finance)

Link: https://finance.yahoo.com/markets/article/october-may-not-be-as-bad-for-the-stock-market-as-investors-think-chart-of-the-day-100000199.html

What Should IBM Stock Investors Be Watching Now? (source: Trefis)

Link: https://finance.yahoo.com/markets/stocks/articles/ibm-stock-investors-watching-now-092255654.html

What Could Go Wrong With Palantir Stock? (source: Trefis)

Link: https://finance.yahoo.com/markets/stocks/articles/could-wrong-palantir-stock-090518407.html

Secure File Transfer Market Forecasts Growth from $5.69B (2026) to $8.34B by 2031, Profiling IBM, Fortra, OPSWAT, Axway & Oracle (source: GlobeNewswire)

Link: https://finance.yahoo.com/technology/articles/secure-file-transfer-market-forecasts-080400427.html

Quantum Computing Is Having a Moment. What to Know About the Hottest Sector After AI. (source: Barrons.com)

Link: https://finance.yahoo.com/m/ee2c0ec8-7fb9-386b-a8bd-92a7ae40c81d/quantum-computing-is-having-a.html

New IBM CHRO Study: Canadian Employees Worry AI Is Eroding Skills as Critical Thinking Gains Importance (source: CNW Group)

Link: https://finance.yahoo.com/technology/ai/articles/ibm-chro-study-canadian-employees-040100207.html

EPAM, DXC, Everforth, EXL, and Grid Dynamics Stocks Trade Up, What You Need To Know (source: StockStory)

Link: https://finance.yahoo.com/markets/stocks/articles/epam-dxc-everforth-exl-grid-224507189.html

Concentrix, Huron, and TaskUs Shares Skyrocket, What You Need To Know (source: StockStory)

Link: https://finance.yahoo.com/markets/stocks/articles/concentrix-huron-taskus-shares-skyrocket-222907764.html

Better Quantum Computing Stock: IonQ vs. D-Wave (source: Motley Fool)

Link: https://finance.yahoo.com/markets/stocks/articles/better-quantum-computing-stock-ionq-213500639.html

================================== Ai Message ==================================
Tool Calls:
get_macro_indicators (tool_NorpI1ShnNy1BChM9oSk3ad9)
Call ID: tool_NorpI1ShnNy1BChM9oSk3ad9
Args:
indicator: cpi
curr_date: 2026-10-02
look_back_days: 180
get_macro_indicators (tool_GBVtNH38yfdUZOXPtlLyGAna)
Call ID: tool_GBVtNH38yfdUZOXPtlLyGAna
Args:
indicator: fed_funds_rate
curr_date: 2026-10-02
get_macro_indicators (tool_UBhz6WSdSf6P4FnLyGMHqX0Y)
Call ID: tool_UBhz6WSdSf6P4FnLyGMHqX0Y
Args:
indicator: 10y_treasury
curr_date: 2026-10-02
get_macro_indicators (tool_j2zYIhtWwNQfVJTGdaQRjppc)
Call ID: tool_j2zYIhtWwNQfVJTGdaQRjppc
Args:
indicator: vix
curr_date: 2026-10-02
get_prediction_markets (tool_BbbBbceZ7TKePrri94U6mAdp)
Call ID: tool_BbbBbceZ7TKePrri94U6mAdp
Args:
topic: Fed rate cut October 2026
================================= Tool Message =================================
Name: get_prediction_markets

Polymarket prediction markets: "Fed rate cut October 2026"

Live, market-implied probabilities (higher traded volume = deeper, more reliable). A probability is the crowd's priced odds of the event, not a forecast you should take as certain.

Fed rate cut by December 2026 meeting? — Yes 2% ($379,040 volume, resolves 2027-01-29, 1-week -0.6pp)
Fed rate cut by October 2026 meeting? — Yes 1% ($206,380 volume, resolves 2027-01-29, 1-week -0.2pp)
Fed rate cut by January 2027 meeting? — Yes 6% ($568 volume, resolves 2027-02-08, 1-week -4.5pp)
Fed rate cut by March 2027 meeting? — Yes 22% ($397 volume, resolves 2027-04-08, 1-week -1.0pp)
Fed rate cut by July 2027 meeting? — Yes 59% ($102 volume, resolves 2027-08-08, 1-week +14.5pp)
Fed rate cut by April 2027 meeting? — Yes 39% ($50 volume, resolves 2027-05-08, 1-week +9.5pp)

================================== Ai Message ==================================
Tool Calls:
get_prediction_markets (tool_Tz2h0ugM2Gv6GFdzmu8Dw8Hy)
Call ID: tool_Tz2h0ugM2Gv6GFdzmu8Dw8Hy
Args:
topic: US recession 2026
get_prediction_markets (tool_zGFOhfhplqE3XE8MjbGGCYyc)
Call ID: tool_zGFOhfhplqE3XE8MjbGGCYyc
Args:
topic: biotech healthcare sector
get_global_news (tool_k4NjKsy56AihLTZK0qtk7anI)
Call ID: tool_k4NjKsy56AihLTZK0qtk7anI
Args:
curr_date: 2026-10-02
look_back_days: 7
limit: 20
================================= Tool Message =================================
Name: get_global_news

Global Market News, from 2026-09-25 to 2026-10-02:

The Iran war is driving inflation higher — and it's not just because of oil (source: Yahoo Finance)

Link: https://finance.yahoo.com/markets/article/the-iran-war-is-driving-inflation-higher--and-its-not-just-because-of-oil-100000797.html

October may not be as bad for the stock market as investors think: Chart of the Day (source: Yahoo Finance)

Link: https://finance.yahoo.com/markets/article/october-may-not-be-as-bad-for-the-stock-market-as-investors-think-chart-of-the-day-100000199.html

What Should IBM Stock Investors Be Watching Now? (source: Trefis)

Link: https://finance.yahoo.com/markets/stocks/articles/ibm-stock-investors-watching-now-092255654.html

What Could Go Wrong With Palantir Stock? (source: Trefis)

Link: https://finance.yahoo.com/markets/stocks/articles/could-wrong-palantir-stock-090518407.html

Secure File Transfer Market Forecasts Growth from $5.69B (2026) to $8.34B by 2031, Profiling IBM, Fortra, OPSWAT, Axway & Oracle (source: GlobeNewswire)

Link: https://finance.yahoo.com/technology/articles/secure-file-transfer-market-forecasts-080400427.html

Quantum Computing Is Having a Moment. What to Know About the Hottest Sector After AI. (source: Barrons.com)

Link: https://finance.yahoo.com/m/ee2c0ec8-7fb9-386b-a8bd-92a7ae40c81d/quantum-computing-is-having-a.html

New IBM CHRO Study: Canadian Employees Worry AI Is Eroding Skills as Critical Thinking Gains Importance (source: CNW Group)

Link: https://finance.yahoo.com/technology/ai/articles/ibm-chro-study-canadian-employees-040100207.html

EPAM, DXC, Everforth, EXL, and Grid Dynamics Stocks Trade Up, What You Need To Know (source: StockStory)

Link: https://finance.yahoo.com/markets/stocks/articles/epam-dxc-everforth-exl-grid-224507189.html

Concentrix, Huron, and TaskUs Shares Skyrocket, What You Need To Know (source: StockStory)

Link: https://finance.yahoo.com/markets/stocks/articles/concentrix-huron-taskus-shares-skyrocket-222907764.html

Better Quantum Computing Stock: IonQ vs. D-Wave (source: Motley Fool)

Link: https://finance.yahoo.com/markets/stocks/articles/better-quantum-computing-stock-ionq-213500639.html

Why IBM (IBM) Stock Is Trading Up Today (source: StockStory)

Link: https://finance.yahoo.com/markets/stocks/articles/why-ibm-ibm-stock-trading-211707996.html

Why IBM Stock Is Getting a Much-Needed Boost From Accenture Earnings (source: Barrons.com)

Link: https://finance.yahoo.com/m/5ef0359e-b826-39c2-bb3d-48a3aab0029e/why-ibm-stock-is-getting-a.html

IBM Elects Siris Capital Co-Founder Frank Baker to Board (source: MT Newswires)

Link: https://finance.yahoo.com/markets/stocks/articles/ibm-elects-siris-capital-co-210726334.html

IBM (IBM) Rises Higher Than Market: Key Facts (source: Zacks)

Link: https://finance.yahoo.com/markets/stocks/articles/ibm-ibm-rises-higher-market-204506913.html

IBM Elects Frank Baker to its Board of Directors (source: PR Newswire)

Link: https://finance.yahoo.com/markets/stocks/articles/ibm-elects-frank-baker-board-201500181.html

Micron, Accenture, Google, IBM, Fair Isaac, Synopsys, and More Stocks That Explain Today’s Market (source: Barrons.com)

Link: https://finance.yahoo.com/m/ff733662-6b3b-3329-895d-f9bd4d70a5b2/micron%2C-accenture%2C-google%2C.html

Top 3 Cybersecurity Stocks To Watch In October 2026 (source: Simply Wall St.)

Link: https://finance.yahoo.com/markets/stocks/articles/top-3-cybersecurity-stocks-watch-201030761.html

Stock market today: Dow, S&P 500, Nasdaq stage comeback as Treasury yields fall, chip stocks gain (source: Yahoo Finance)

Link: https://finance.yahoo.com/markets/live/stock-market-today-thursday-oct-1-dow-sp-500-nasdaq-080602402.html

Americas Gold and Silver Targets 5M Ounces as Galena Overhaul Gains Momentum (source: MarketBeat)

Link: https://finance.yahoo.com/markets/commodities/articles/americas-gold-silver-targets-5m-090205096.html

Comstock Launches 24/7 Solar Panel Recycling at Nevada Facility (source: MarketBeat)

Link: https://finance.yahoo.com/energy/articles/comstock-launches-24-7-solar-060203686.html

================================== Ai Message ==================================
Tool Calls:
get_news (tool_LRuY2qZ0Q3MFGzrn9e6XmPLM)
Call ID: tool_LRuY2qZ0Q3MFGzrn9e6XmPLM
Args:
ticker: CORT
start_date: 2026-09-01
end_date: 2026-10-02
get_prediction_markets (tool_4aNMtt68AR8hnmpUje76tTOr)
Call ID: tool_4aNMtt68AR8hnmpUje76tTOr
Args:
topic: Iran war oil
================================= Tool Message =================================
Name: get_prediction_markets

Polymarket prediction markets: "Iran war oil"

Live, market-implied probabilities (higher traded volume = deeper, more reliable). A probability is the crowd's priced odds of the event, not a forecast you should take as certain.

No open prediction markets matched 'Iran war oil'. Polymarket coverage is concentrated in macro, political, geopolitical, and crypto events; a specific equity may have none.
================================== Ai Message ==================================
Tool Calls:
get_prediction_markets (tool_vF95qSdVAkToAnlb2ueP0Gam)
Call ID: tool_vF95qSdVAkToAnlb2ueP0Gam
Args:
topic: Iran conflict
================================= Tool Message =================================
Name: get_prediction_markets

Polymarket prediction markets: "Iran conflict"

Live, market-implied probabilities (higher traded volume = deeper, more reliable). A probability is the crowd's priced odds of the event, not a forecast you should take as certain.

No open prediction markets matched 'Iran conflict'. Polymarket coverage is concentrated in macro, political, geopolitical, and crypto events; a specific equity may have none.
================================== Ai Message ==================================

Global Macro & News Research Report — CORT (Corcept Therapeutics) Context

Analysis date: 2026-10-02 | Coverage window: 2026-09-25 → 2026-10-02

1. Executive Summary

The past week has been characterized by three dominant themes relevant to equity and macro positioning:

Geopolitical inflation shock: The ongoing Iran conflict is feeding through to inflation beyond energy channels (supply-chain, freight, insurance costs), keeping upward pressure on prices and complicating the Fed's path.
A hawkish-rate regime that markets have fully priced: Prediction markets imply only ~1–2% odds of a Fed rate cut at the October 2026 meeting, ~2% by December 2026, and no >50% probability of a cut until July 2027. This is a "higher-for-longer" rate environment.
Risk appetite is holding up better than feared: Major indices staged a comeback on Oct 1 as Treasury yields fell and chip stocks gained; recession odds remain low at 8% for 2026.

For CORT (Corcept Therapeutics) specifically, the news feed returned no company-specific headlines in the trailing month, meaning the stock is currently trading on sector/macro flows rather than idiosyncratic catalysts. This is itself actionable information: without a catalyst, CORT's near-term performance will be driven by biotech sector rotation, rates, and any latent regulatory/commercial developments.

2. Company-Specific Findings: CORT

News search 2026-09-25 → 2026-10-02: No articles found.
Extended search 2026-09-01 → 2026-10-02: No articles found.

Interpretation:
- No fresh catalysts (clinical data, FDA milestones, litigation updates, earnings pre-announcements) surfaced in this window. Corcept's fundamentals rest primarily on its cortisol-modulating franchise (Korlym/relacorilant for Cushing's syndrome) and its pipeline expansion into metabolic, oncology, and psychiatric indications.
- Risk flag: A biotech with an empty news tape can be especially sensitive to (a) unexpected regulatory/commercial headlines, (b) short-seller reports, and (c) healthcare policy news (drug pricing, PBM reform, IRA provisions). Position sizing should account for gap risk.
- Actionable angle: With no news-driven momentum, CORT is a candidate for technical/flow-based trading rather than event-driven trading this week. Any sudden volume spike should be investigated for an unscheduled catalyst.

3. Macroeconomic Backdrop

3.1 Inflation: The Iran war dimension

Yahoo Finance highlights that the Iran war is pushing inflation higher beyond oil — second-order effects through shipping, insurance, and input costs. For the Fed, this means sticky inflation components even if headline energy stabilizes. Implication: the bar for cuts rises, duration-sensitive and speculative-duration assets (long-dated biotech cash flows) face continued headwinds from elevated discount rates.

3.2 Fed Policy Path (Polymarket-implied probabilities)

Market	Implied Prob.	Volume	1-week move
Rate cut by Oct 2026 meeting	1%	$206K	−0.2pp
Rate cut by Dec 2026 meeting	2%	$379K	−0.6pp
Rate cut by Jan 2027	6%	low vol	−4.5pp
Rate cut by Mar 2027	22%	low vol	−1.0pp
Rate cut by Jul 2027	59%	low vol	+14.5pp

The market has essentially written off cuts through year-end. The sharp week-over-week rise in 2027 cut odds (July +14.5pp, April +9.5pp) suggests traders are positioning for easing to begin mid-2027. High-for-longer rates = headwind for high-multiple biotech; a mid-2027 easing window is a medium-term tailwind for the sector.

3.3 Growth / Recession

US recession by end-2026: 8% ($2.2M volume, down 1.0pp on the week). Consensus firmly rejects a near-term recession; this supports risk-on equity positioning generally.

3.4 Equity Market Tone

Headline (Oct 1): "Dow, S&P 500, Nasdaq stage comeback as Treasury yields fall, chip stocks gain" — falling yields lifting growth/tech is a constructive cross-read for biotech.
"October may not be as bad as investors think" — seasonal fear may be overstated; dips could be bought.
Note: Macro indicator pulls from FRED (CPI, fed funds, 10Y, VIX) were unavailable this session (API key not configured), so rate/inflation levels are inferred from news and prediction-market pricing rather than hard data. A follow-up pass with FRED access is recommended.

4. Sector & Cross-Asset Observations

Quantum computing / AI is dominating speculative flows (IonQ, D-Wave, IBM coverage), potentially crowding out biotech as the preferred high-beta destination — a marginal negative for CORT's flow profile.
Gold/silver mining strength (Americas Gold & Silver) suggests persistent hedging demand despite low recession odds — investors hedging the geopolitical tail even as the base case stays bullish.
No direct healthcare/biotech sector headlines appeared in the global feed this week — healthcare is not in the spotlight, implying neutral sector rotation.

5. Actionable Insights for CORT Traders

No idiosyncratic catalyst → trade the beta, not the story. CORT will track XBI/IBB and the rates complex. Watch the 10-year yield: falling yields on Oct 1 lifted growth stocks broadly; a sustained yield decline is the single best macro tailwind available to CORT right now.
Hawkish Fed is the key headwind. With ~1% odds of an October cut, don't position for a rate-driven biotech rally in Q4 2026. If CPI re-accelerates on Iran-war pass-through, expect multiple compression in high-beta biotech.
Watch for latent catalysts. Corcept typically moves on: FDA milestones for relacorilant expanded indications, Phase 2/3 data readouts, and patent/litigation developments. The empty news tape raises the probability that the next headline is a gap-inducing event — use options or defined-risk structures if carrying overnight exposure.
Geopolitical inflation hedge logic cuts both ways: persistent inflation is bad for duration assets (CORT), but a biotech with real revenue (Corcept is profitable, not a pre-revenue story) is more resilient than speculative names if risk appetite cracks.
Recession at 8% = no defensive rotation signal needed yet; stay risk-aware but not risk-off.

6. Key Data Summary Table

Theme	Data Point (source)	Trading Implication for CORT
CORT news flow	No headlines, Sep 1 – Oct 2	No catalyst; trade sector/rates beta; gap-risk if headline appears
Fed cut by Oct 2026	1% (Polymarket, $206K vol)	No near-term rate relief priced; headwind for biotech multiples
Fed cut by Dec 2026	2% (Polymarket, $379K vol)	Q4 rally unlikely to be Fed-driven
First >50% cut odds	July 2027 (59%, +14.5pp wk/wk)	Medium-term easing tailwind; medium-term bullish sector
US recession by end-2026	8% ($2.2M vol, −1.0pp)	Risk-on regime intact; no defensive shift required
Iran war inflation	Broadening past oil (Yahoo Finance)	Sticky inflation → higher-for-longer → negative for duration/biotech
Oct 1 market action	Indices rally as yields fall, chips gain	Falling yields lifting growth = constructive template for biotech
October seasonality	"May not be as bad as feared" (Yahoo)	Seasonal fear overstated; favor buying dips
Speculative flows	Quantum/AI dominating headlines	Biotech being crowded out of high-beta flows — mild negative
FRED macro data	Unavailable (API key missing)	Follow-up needed to confirm CPI/yield levels

Bottom line: CORT enters October with a clean news slate in a market that is risk-on but rate-constrained. The trade setup is: respect the hawkish-Fed headwind on multiples, benefit from resilient risk appetite and any yield declines, and stay alert for the gap-risk catalyst that an empty news tape tends to precede.
================================ Human Message =================================

I'll analyze Corcept Therapeutics (CORT) by gathering its fundamental data and financial statements.
Tool Calls:
get_fundamentals (tool_GuBUfyoeb4nv6FJIG82DNan3)
Call ID: tool_GuBUfyoeb4nv6FJIG82DNan3
Args:
ticker: CORT
curr_date: 2026-10-02
get_balance_sheet (tool_wyj5helM2yCPaNOkxZtlAAq3)
Call ID: tool_wyj5helM2yCPaNOkxZtlAAq3
Args:
ticker: CORT
curr_date: 2026-10-02
get_income_statement (tool_HZpDT8JmNvg8EaQBh8WcelYT)
Call ID: tool_HZpDT8JmNvg8EaQBh8WcelYT
Args:
ticker: CORT
curr_date: 2026-10-02
get_cashflow (tool_eOADnBQ0f5dYrGtpCK2yb36d)
Call ID: tool_eOADnBQ0f5dYrGtpCK2yb36d
Args:
ticker: CORT
curr_date: 2026-10-02
================================= Tool Message =================================
Name: get_cashflow

Cash Flow data for CORT (quarterly)

Data retrieved on: 2026-10-02 13:14:38

,2026-06-30,2026-03-31,2025-12-31,2025-09-30,2025-06-30,2025-03-31
Free Cash Flow,31015000.0,-16973000.0,38398000.0,54481000.0,44240000.0,
Capital Expenditure,-2528000.0,-201000.0,-50000.0,,-57000.0,-104000.0
End Cash Position,112289000.0,109988000.0,120495000.0,125138000.0,103745000.0,
Beginning Cash Position,109988000.0,121745000.0,125138000.0,103745000.0,90819000.0,
Effect Of Exchange Rate Changes,37000.0,-287000.0,-32000.0,-320000.0,1436000.0,
Changes In Cash,2264000.0,-11470000.0,-4611000.0,22713000.0,11490000.0,
Financing Cash Flow,-2037000.0,760000.0,-31216000.0,-46413000.0,-102934000.0,
Cash Flow From Continuing Financing Activities,-2037000.0,760000.0,-31216000.0,-46413000.0,-102934000.0,
Net Other Financing Charges,-11457000.0,-5761000.0,-36538000.0,-8152000.0,-12426000.0,
Proceeds From Stock Option Exercised,9420000.0,6521000.0,5322000.0,-38261000.0,-90508000.0,
Investing Cash Flow,-29242000.0,4542000.0,-11843000.0,14645000.0,70127000.0,
Cash Flow From Continuing Investing Activities,-29242000.0,4542000.0,-11843000.0,14645000.0,70127000.0,
Net Investment Purchase And Sale,-26714000.0,4743000.0,-11793000.0,14645000.0,70184000.0,
Sale Of Investment,62241000.0,57071000.0,132040000.0,52000000.0,93458000.0,
Purchase Of Investment,-88955000.0,-52328000.0,-143833000.0,-37355000.0,-23274000.0,
Net PPE Purchase And Sale,-2528000.0,-201000.0,-50000.0,0.0,-57000.0,
Purchase Of PPE,-2528000.0,-201000.0,-50000.0,0.0,-57000.0,
Operating Cash Flow,33543000.0,-16772000.0,38448000.0,54481000.0,44297000.0,
Cash Flow From Continuing Operating Activities,33543000.0,-16772000.0,38448000.0,54481000.0,44297000.0,
Change In Working Capital,-41897000.0,5294000.0,9185000.0,3348000.0,8732000.0,
Change In Other Current Liabilities,,,-251000.0,-247000.0,-230000.0,-101000.0
Change In Other Current Assets,,,2896000.0,254000.0,-1693000.0,0.0
Change In Payables And Accrued Expense,3611000.0,-16884000.0,-562000.0,26138000.0,6506000.0,
Change In Accrued Expense,21852000.0,-9240000.0,-7604000.0,15169000.0,10928000.0,
Change In Payable,-18241000.0,-7644000.0,7042000.0,10969000.0,-4422000.0,
Change In Account Payable,-18241000.0,-7644000.0,5998000.0,10921000.0,-4422000.0,
Change In Tax Payable,,,1044000.0,-1545000.0,1424000.0,169000.0
Change In Income Tax Payable,,,1044000.0,-1545000.0,1424000.0,169000.0
Change In Prepaid Assets,-3396000.0,4736000.0,-3224000.0,-11768000.0,9600000.0,
Change In Inventory,-4264000.0,-3272000.0,483000.0,-3943000.0,-4626000.0,
Change In Receivables,-37848000.0,20714000.0,9843000.0,-5062000.0,-2748000.0,
Changes In Account Receivables,-37848000.0,20714000.0,9843000.0,-5062000.0,-2748000.0,
Stock Based Compensation,29416000.0,23043000.0,20768000.0,22879000.0,19023000.0,
Amortization Of Securities,-707000.0,-836000.0,-1093000.0,-1005000.0,-1312000.0,
Deferred Tax,2881000.0,-13110000.0,-15182000.0,9114000.0,-17764000.0,
Deferred Income Tax,2881000.0,-13110000.0,-15182000.0,9114000.0,-17764000.0,
Depreciation Amortization Depletion,863000.0,598000.0,482000.0,477000.0,469000.0,
Depreciation And Amortization,863000.0,598000.0,482000.0,477000.0,469000.0,
Depreciation,,598000.0,482000.0,477000.0,469000.0,462000.0
Net Income From Continuing Operations,42987000.0,-31761000.0,24288000.0,19668000.0,35149000.0,

================================== Ai Message ==================================

Let me also pull the annual statements to add historical context.
Tool Calls:
get_income_statement (tool_s1gzuEe1Md64P37EKYfct1Zt)
Call ID: tool_s1gzuEe1Md64P37EKYfct1Zt
Args:
ticker: CORT
freq: annual
curr_date: 2026-10-02
get_cashflow (tool_ZBGJsv0jm4G2shen1RdwHrLn)
Call ID: tool_ZBGJsv0jm4G2shen1RdwHrLn
Args:
ticker: CORT
freq: annual
curr_date: 2026-10-02
================================= Tool Message =================================
Name: get_cashflow

Cash Flow data for CORT (annual)

Data retrieved on: 2026-10-02 13:14:42

,2025-12-31,2024-12-31,2023-12-31,2022-12-31,2021-12-31
Free Cash Flow,141785000.0,196123000.0,126542000.0,119910000.0,
Repurchase Of Capital Stock,0.0,0.0,-145428000.0,0.0,
Capital Expenditure,-211000.0,-2172000.0,-139000.0,-413000.0,
Income Tax Paid Supplemental Data,12969000.0,60267000.0,47602000.0,39747000.0,
End Cash Position,120495000.0,127665000.0,135551000.0,66329000.0,
Beginning Cash Position,127665000.0,135551000.0,66329000.0,77617000.0,
Effect Of Exchange Rate Changes,1442000.0,-228000.0,358000.0,,
Changes In Cash,-8612000.0,-7658000.0,68864000.0,-11288000.0,
Financing Cash Flow,-220366000.0,-28349000.0,-148723000.0,-17284000.0,
Cash Flow From Continuing Financing Activities,-220366000.0,-28349000.0,-148723000.0,-17284000.0,
Net Other Financing Charges,-72941000.0,-22301000.0,-9106000.0,-21665000.0,
Proceeds From Stock Option Exercised,-147425000.0,-6048000.0,5811000.0,4381000.0,
Net Common Stock Issuance,0.0,0.0,-145428000.0,0.0,
Common Stock Payments,0.0,0.0,-145428000.0,0.0,
Investing Cash Flow,69758000.0,-177604000.0,90906000.0,-114327000.0,
Cash Flow From Continuing Investing Activities,69758000.0,-177604000.0,90906000.0,-114327000.0,
Net Investment Purchase And Sale,69969000.0,-175432000.0,91045000.0,-113914000.0,
Sale Of Investment,389576000.0,412878000.0,419793000.0,241152000.0,
Purchase Of Investment,-319607000.0,-588310000.0,-328748000.0,-355066000.0,
Net PPE Purchase And Sale,-211000.0,-2172000.0,-139000.0,-413000.0,
Purchase Of PPE,-211000.0,-2172000.0,-139000.0,-413000.0,
Operating Cash Flow,141996000.0,198295000.0,126681000.0,120323000.0,
Cash Flow From Continuing Operating Activities,141996000.0,198295000.0,126681000.0,120323000.0,
Change In Working Capital,-1406000.0,45525000.0,7860000.0,5539000.0,
Change In Other Current Liabilities,-829000.0,183000.0,-1289000.0,-2199000.0,
Change In Other Current Assets,1457000.0,-69000.0,-1483000.0,-1975000.0,
Change In Payables And Accrued Expense,30174000.0,38537000.0,31036000.0,32503000.0,
Change In Accrued Expense,4014000.0,36780000.0,24406000.0,19058000.0,
Change In Payable,26160000.0,1757000.0,6630000.0,13445000.0,
Change In Account Payable,25068000.0,-2020000.0,5420000.0,4757000.0,
Change In Tax Payable,1092000.0,3777000.0,1210000.0,8688000.0,
Change In Income Tax Payable,1092000.0,3777000.0,1210000.0,8688000.0,
Change In Prepaid Assets,-18917000.0,5422000.0,-11603000.0,-6557000.0,
Change In Inventory,-7481000.0,305000.0,1265000.0,1199000.0,
Change In Receivables,-5810000.0,1147000.0,-10066000.0,-17432000.0,
Changes In Account Receivables,-5810000.0,-12853000.0,-10066000.0,-3432000.0,
Other Non Cash Items,,,,1383000.0,10000.0
Stock Based Compensation,84500000.0,61354000.0,48940000.0,42442000.0,
Amortization Of Securities,-5103000.0,-10938000.0,-9128000.0,1383000.0,
Deferred Tax,-37537000.0,-40191000.0,-29493000.0,-33905000.0,
Deferred Income Tax,-37537000.0,-40191000.0,-29493000.0,-33905000.0,
Depreciation Amortization Depletion,1890000.0,1336000.0,2362000.0,3446000.0,
Depreciation And Amortization,1890000.0,1336000.0,2362000.0,3446000.0,
Amortization Cash Flow,,,465000.0,477000.0,409000.0
Amortization Of Intangibles,,,465000.0,477000.0,409000.0
Depreciation,1890000.0,1336000.0,2362000.0,3446000.0,
Net Income From Continuing Operations,99652000.0,141209000.0,106140000.0,101418000.0,

================================== Ai Message ==================================

I now have a comprehensive dataset for CORT. Here is the full fundamental research report.

Corcept Therapeutics Incorporated (CORT) — Fundamental Research Report

Analysis Date: 2026-10-02 | Exchange: NCM (Nasdaq) | Sector: Healthcare / Biotechnology

1. Company Profile & Business Overview

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on cortisol modulation. Its lead commercial product is Korlym (mifepristone), approved for Cushing's syndrome (hypercortisolism), and the company is developing relacorilant — a next-generation selective glucocorticoid receptor modulator — across multiple indications including Cushing's syndrome, ovarian cancer, adrenal cancer, and metabolic disease. Revenue is highly concentrated in a single approved franchise, making pipeline outcomes and any exclusivity/regulatory developments the dominant fundamental drivers.

2. Market Snapshot (as of 2026-10-02)

Metric	Value
Market Cap	~$12.33B
Price (implied)	~$114 (trading between 50-day avg $112.14 and 52-week high $126.38)
52-Week High / Low	$126.38 / $28.66 (stock up ~4x off lows)
50-Day / 200-Day Avg	$112.14 / $69.65
Beta	0.45 (low volatility relative to market)
P/E (TTM)	259.1
Forward P/E	25.9
PEG Ratio	0.81
Price/Book	17.4
Book Value/Share	$6.54

Key observation: The stock has re-rated dramatically (200-day average of $69.65 vs. current ~$114). TTM P/E of 259x reflects depressed trailing earnings — forward P/E of 25.9x implies the market expects a major earnings inflection (forward EPS estimate $4.40 vs. TTM EPS $0.44).

3. Income Statement Analysis

Quarterly Trend (Q2 2026 latest reported)

Q2 2026 Revenue: $256.1M (+~32% YoY vs. $194.4M in Q2 2025) — strong acceleration
Q2 2026 Gross Profit: $252.1M (gross margin ~98.4%, typical of specialty pharma)
Q2 2026 Operating Income: $41.3M vs. $26.7M in Q2 2025 — operating leverage improving
Q2 2026 Net Income: $43.0M ($0.36 diluted EPS)
Q1 2026 was a loss quarter: Net income -$31.8M (-$0.30 EPS), driven by SG&A of $145.4M and R&D of $66.3M — high quarter-to-quarter volatility in expense timing

Critical expense trend: Total operating expenses have grown aggressively:
| Year | Total OpEx | R&D | SG&A |
|---|---|---|---|
| FY2022 | $283.8M | $131.0M | $152.8M |
| FY2023 | $368.6M | $184.4M | $184.3M |
| FY2024 | $527.2M | $246.9M | $280.3M |
| FY2025 | $703.6M | $254.9M | $448.7M |

SG&A grew 60% YoY in 2025, far outpacing revenue growth of 12.8% — this is a red flag on operating discipline. Q2 2026 SG&A of $156.9M in a single quarter annualizes to ~$628M.

Annual Trend

Year	Revenue	Net Income	Diluted EPS	EBITDA
FY2022	$401.9M	$101.4M	$0.87	$116.1M
FY2023	$482.4M	$106.1M	$0.94	$109.6M
FY2024	$675.0M	$141.2M	$1.23	$138.3M
FY2025	$761.4M	$99.7M	$0.82	$46.7M

Revenue CAGR (2022–2025) ≈ 23.8% — solid. However, FY2025 net income declined 29% despite revenue growth, as operating expenses grew 33.5%. EBITDA compressed from $138.3M to $46.7M. The 2026 Q2 recovery (revenue +32% YoY, operating income +55% YoY) is encouraging.

4. Balance Sheet Analysis

The balance sheet is strong with no meaningful financial debt:
| Item (Q2 2026) | Value |
|---|---|
| Total Assets | $888.7M |
| Stockholders' Equity | $705.8M |
| Total Debt (capital leases) | $9.4M |
| Cash + Short-Term Investments | $308.2M |
| Current Ratio | 2.86 |
| Debt/Equity | 1.34 (entirely lease obligations, not financial debt) |
| Working Capital | $285.9M |

Strengths:
- $308M in cash/investments; $236.5M in available-for-sale securities provide liquidity
- Current ratio of 2.86 indicates strong short-term liquidity
- Retained earnings positive and growing ($654.6M)

Watch items:
- Accounts Receivable surged to $76.9M in Q2 2026 from $39.1M in Q1 2026 (+97% QoQ) — receivables growing much faster than quarterly revenue (~$256M/quarter implies ~85 days of sales outstanding, up from ~21 days in Q1). This warrants monitoring for channel stuffing or collection issues.
- Treasury stock grew to $998.0M — the company has been an aggressive repurchaser ($145.4M in FY2023, significant buybacks in 2025). Share count has declined from ~141M issued to ~108M ordinary shares outstanding, which is EPS-accretive.
- Deferred revenue (current) of $45.9M is building, which is a positive forward indicator.

5. Cash Flow Analysis

Annual Free Cash Flow Trend

Year	Operating CF	FCF
FY2022	$120.3M	$119.9M
FY2023	$126.7M	$126.5M
FY2024	$198.3M	$196.1M
FY2025	$142.0M	$141.8M

CORT has been consistently free-cash-flow positive with minimal capex needs (asset-light model). FY2025 FCF declined ~28% YoY, consistent with the earnings compression.

Quarterly FCF Volatility

Q2 2026: +$31.0M (solid recovery)
Q1 2026: -$17.0M (operating cash flow was -$16.8M in Q1)
FY2025 quarterly FCF: $44.2M, $54.5M, $38.4M, -$17.0M

Key caveat — Stock-Based Compensation: SBC has grown substantially and represents a large quality-of-earnings adjustment:
- FY2022: $42.4M → FY2023: $48.9M → FY2024: $61.4M → FY2025: $84.5M
- Q2 2026 alone: $29.4M (nearly 70% of net income)

SBC of $84.5M in FY2025 against net income of $99.7M means the majority of "earnings" are offset by share-based dilution. The buyback program is effectively neutralizing this dilution, but traders should treat reported EPS with caution.

6. Key Risks and Considerations

Single-product concentration: Revenue is overwhelmingly dependent on the mifepristone/Korlym franchise. Any generic challenge, regulatory setback, or competitive entry would be materially negative.
Valuation risk: At ~$114/share with TTM EPS of $0.44, the stock trades at 259x trailing earnings. The forward P/E of 25.9x requires the earnings inflection (forward EPS $4.40) to materialize — likely predicated on relacorilant approval/launch. A pipeline disappointment could trigger severe multiple compression.
Expense growth outpacing revenue: SG&A grew 60% in FY2025. If Q2 2026's revenue acceleration doesn't sustain, margins will compress again.
Receivables spike: The 97% QoQ jump in AR needs explanation in the next earnings call.
Q1 seasonality/volatility: Q1 2026 posted a significant loss (-$31.8M net income), showing earnings can swing sharply quarter to quarter.

7. Summary Table of Key Metrics

Category	Metric	Value	Assessment
Valuation	P/E (TTM) / Forward P/E	259x / 25.9x	Trailing rich; forward depends on pipeline
Valuation	PEG Ratio	0.81	Reasonable if growth materializes
Valuation	P/B	17.4x	High; reflects intangible/pipeline value
Growth	Revenue CAGR (22–25)	~23.8%	Strong
Growth	Q2 2026 Revenue YoY	+31.8%	Accelerating
Profitability	Gross Margin	~98%	Excellent
Profitability	Operating Margin (TTM)	16.1%	Compressed vs. FY2024
Profitability	Net Margin (TTM)	6.6%	Weak for the valuation
Quality	FCF (FY2025)	$141.8M	Positive, but down 28% YoY
Quality	SBC (FY2025)	$84.5M	High; ~85% of net income
Balance Sheet	Current Ratio	2.86	Strong
Balance Sheet	Cash + ST Investments	$308.2M	Solid runway
Balance Sheet	Financial Debt	~$0 (leases only)	Very low leverage
Momentum	52-week range	$28.66–$126.38	~4x rally off lows
Momentum	Price vs. 200-day	~64% above	Strong uptrend
Red Flags	AR growth (Q2 QoQ)	+97%	Monitor
Red Flags	FY2025 earnings decline	-29% YoY	Watch expense growth

Bottom Line for Traders: CORT presents a classic biotech "show-me" story. The balance sheet is fortress-like and the company is FCF-positive with accelerating revenue growth in Q2 2026 (+32% YoY). However, the stock price has already re-rated dramatically (near 52-week highs, ~64% above the 200-day average), the trailing P/E of 259x embeds enormous expectations, and FY2025 demonstrated that aggressive expense growth can quickly erode profitability. The forward thesis hinges on relacorilant/pipeline execution. Existing holders may consider holding with tight risk management given the strong balance sheet and momentum; new buyers should be cautious chasing the stock at current levels near its 52-week high, and should watch the AR spike and quarterly expense trends closely. The 0.81 PEG and forward P/E of 25.9x become attractive only if the projected earnings inflection is confirmed in coming quarters.
================================ Human Message =================================

Action: Hold

Reasoning: CORT's secular uptrend remains intact (price 63% above the 200 SMA at $69.78, 50 SMA rising every session to $112.61) and the five-week flag between ~$108 and $120 shows bullish consolidation behavior (RSI 50.5 holding the 45–58 band, no distribution volume). However, short-term momentum has rolled over — price sits below the 10 EMA ($114.80), MACD has crossed below signal with a negative histogram, and repeated failures above $120 warn that timing for new longs is unconfirmed. The research plan's fundamentals are mixed (strong Korlym franchise and cash position versus unproven Lifyorli ramp, 97% receivables growth, and dependence on year-end FDA/EMA binary events), so neither aggressive initiation nor exit is warranted. Hold existing exposure with a protective stop just below the $108–110 support shelf (~2x ATR under the mid-band, a $109 stop is ~4.4% below the $114.03 close); a decisive close below that shelf triggers the planned 25–33% reduction, while adds require confirmed breakout above ~$120.5 plus Q3 revenue, receivables, and regulatory validation.

Stop Loss: 109.0

Position Sizing: Maintain current allocation; cap position at a size the portfolio could withstand through a 25–30% adverse catalyst gap. Do not add.

FINAL TRANSACTION PROPOSAL: HOLD

============================================================
FINAL DECISION (CORT, 2026-10-02):
============================================================
Hold

Elapsed: 749s